Research And Markets Research And Markets

RANKL Signaling Pathway in Oncology Drug Pipeline Update

  • ID: 2067700
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily. It binds to Receptor activator of NF-kB (RANK) and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). The RANKL-RANK signaling system is negatively regulated by a decoy receptor known as Osteoprotegerin.

There are today 282 companies plus partners developing 356 RANKL pathway targeting drugs in 1398 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 178 drugs. Rankl Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 155 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 154 out of the 154 studied drug targets so far have READ MORE >

Note: Product cover images may vary from those shown
2 of 2

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown